Enliven Therapeutics Inc. has granted an inducement stock option to Richard Fair, the company's new President and Chief Executive Officer. Fair received an option to purchase 875,000 shares of Enliven's common stock at an exercise price of $18.77 per share, which was the closing price on the grant date. The option will vest with 25% of the shares vesting on the first anniversary of the grant, and the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA44364) on December 11, 2025, and is solely responsible for the information contained therein.